Merck’s “VIGORous” Defense Of Vioxx; Novartis, Wyeth Studies Might Help
Executive Summary
Merck still believes that the initial cardiovascular safety signal seen for Vioxx can be explained by a cardioprotective effect from naproxen, the company said during an Oct. 13 press conference in New York City
You may also be interested in...
Vioxx Importation On The Horizon? Health Canada Open To Rofecoxib Return
Health Canada appears open to the reintroduction of Merck's COX-2 inhibitor Vioxx, Health Canada Manager of Marketed Pharmaceuticals Marc Berthiaume indicated during a July 7 media call
Vioxx Importation On The Horizon? Health Canada Open To Rofecoxib Return
Health Canada appears open to the reintroduction of Merck's COX-2 inhibitor Vioxx, Health Canada Manager of Marketed Pharmaceuticals Marc Berthiaume indicated during a July 7 media call
Merck May Need New Arcoxia Trial Design Prior To FDA Approval
Merck may need to conduct additional Arcoxia clinical trials to gain FDA approval after the agency and its COX-2 inhibitor advisory committee cited flaws in the existing program